Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | KARS1 | Q15046 | 7/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776197 | 0.90 | PRKD3 (0.40) | DYRK1AKARS1RAF1BRAFWNT1 | |
| SCHEMBL16776051 | 0.89 | PRKCI (0.36) | DYRK1AKITCYP3A4ALDH1A1TSHR | |
| SCHEMBL16776163 | 0.88 | FGFR4 (0.40) | DYRK1AKARS1KITSYK | |
| SCHEMBL16776025 | 0.85 | CYP11B2 (0.38) | DYRK1A | |
| SCHEMBL16776147 | 0.83 | KARS1 (0.35) | DYRK1AKARS1ABL1 | |
| SCHEMBL16776011 | 0.81 | CA9 (0.38) | ALDH1A1 | |
| SCHEMBL16776160 | 0.81 | KARS1 (0.40) | DYRK1AKARS1WNT1GSK3B | |
| SCHEMBL16776000 | 0.79 | PRKCI (0.39) | KARS1KITABL1 | |
| SCHEMBL16775916 | 0.79 | FAAH (0.38) | ALDH1A1TSHR | |
| SCHEMBL16776126 | 0.79 | KARS1 (0.39) | KARS1ALDH1A1TSHRCYP2C19SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | DYRK1A 2623/4885KARS1 1760/4885RAF1 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.